Market Place
Sourcing Support
Biohaven Reports Positive Phase 1 Degrader Data, NDA Submission
16 Dec 2024 //
PR NEWSWIRE
Biohaven Achieves Topline Results in Study of Troriluzole in SCA
24 Sep 2024 //
PR NEWSWIRE
Biohaven To Discuss Topline Results in Spinocerebellar Ataxia
20 Sep 2024 //
PR NEWSWIRE
A blow for Biohaven as FDA refuses failed rare disease drug
27 Jul 2023 //
FIERCE BIOTECH
Biohaven adds to a long list of Alzheimer`s drug failures
20 Jan 2021 //
BIOPHARMADIVE
MediciNova Receives Notice of Allowance for New Patent MN-166 (ibudilast)
19 Jan 2021 //
GLOBENEWSWIRE
Biohaven Begins Pivotal Phase 3 Trial Of Troriluzole In Obsessive
04 Jan 2021 //
PRNEWSWIRE
Biohaven reports topline results from phase 2/3 study of troriluzole
25 Jun 2020 //
PHARMABIZ
Biohaven reports another trial failure for troriluzole
24 Jun 2020 //
ENDPTS
Biohaven Announces OCD Proof Of Concept Phase 2/3 Study
24 Jun 2020 //
PRNEWSWIRE
Expanded Data From Troriluzole PhIIb/III Long-Term Extension Study
07 May 2020 //
BIOHAVENPHARMA
Biohaven anxiety treatment fails late-stage study, shares fall 16%
11 Feb 2020 //
REUTERS
Biohaven Announces Issuance of Composition of Matter Patent on Troriluzole
05 Dec 2019 //
PR NEWSWIRE
Biohaven Completes In Pivotal Ph2/3 Alzheimer`s Disease Trial Of Troriluzole
05 Nov 2019 //
PR NEWSWIRE
Biohaven Enrolls First Patient In Ph3 Spinocerebellar Ataxia of Troriluzole
14 Mar 2019 //
PR NEWSWIRE
Biohaven Completes Enrollment In Spinocerebellar Ataxia Clinical Trial With Trigriluzole
30 May 2017 //
CLINICAL LEADER
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.